東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Breast cancer-specific activation of...

Day, Chi-Ping.

FindBook

Google Book

Amazon

博客來

Breast cancer-specific activation of topoisomerase IIalpha and its application in the tumor-targeting gene therapy.

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Breast cancer-specific activation of topoisomerase IIalpha and its application in the tumor-targeting gene therapy./
作者:	Day, Chi-Ping.
面頁冊數:	132 p.
附註:	Source: Dissertation Abstracts International, Volume: 66-06, Section: B, page: 3072.
Contained By:	Dissertation Abstracts International66-06B.
標題:	Biology, Genetics. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3180668
ISBN:	9780542209406

Breast cancer-specific activation of topoisomerase IIalpha and its application in the tumor-targeting gene therapy.
Day, Chi-Ping.

Breast cancer-specific activation of topoisomerase IIalpha and its application in the tumor-targeting gene therapy. - 132 p.

Source: Dissertation Abstracts International, Volume: 66-06, Section: B, page: 3072.

Thesis (Ph.D.)--The University of Texas Graduate School of Biomedical Sciences at Houston, 2005.

To ensure the success of systemic gene therapy, it is critical to enhance the tumor specificity and activity of the promoter. In the current study, we identified the breast cancer-specific activity of the topoisomerase IIalpha promoter. We further showed that cdk2 and cyclin A activate topoisomerase IIalpha promoter in a breast cancer-specific manner. An element containing an inverted CCAAT box (ICB) was shown to respond this signaling. When the ICB-harboring topoisomerase IIalpha minimal promoter was linked with an enhancer sequence from the cytomegalovirus immediate early gene promoter (CMV promoter), this composite promoter, CT90, exhibited activity comparable to or higher than the CMV promoter in breast cancer cells in vitro and in vivo, yet expresses much lower activity in normal cell lines and normal organs than the CMV promoter. A CT90-driven construct expressing BikDD, a potent pro-apoptotic gene, was shown to selectively kill breast cancer cells in vitro and to suppress mammary tumor development in an animal model of intravenously administrated, liposome-delivered gene therapy. Expression of BikDD was readily detectable in the tumors but not in the normal organs of CT90-BikDD-treated animals. Finally, we demonstrated that CT90-BikDD treatment potentially enhanced the sensitivity of breast cancer cells to chemotherapeutic agents, especially doxorubicin and taxol. The results indicate that liposomal CT90-BikDD is a novel and effective systemic breast cancer-targeting gene therapy, and its combination with chemotherapy may further improve the current adjuvant therapy for breast cancer.

ISBN: 9780542209406Subjects--Topical Terms:

1017730
Biology, Genetics.

Breast cancer-specific activation of topoisomerase IIalpha and its application in the tumor-targeting gene therapy.
LDR:02590nam 2200277 a 45 001 972902
005 20110928
008 110928s2005 eng d
020 $a 9780542209406
035 $a (UnM)AAI3180668
035 $a AAI3180668
040 $a UnM $c UnM
100 1 $a Day, Chi-Ping. $3 1296868
245 1 0 $a Breast cancer-specific activation of topoisomerase IIalpha and its application in the tumor-targeting gene therapy.
300 $a 132 p.
500 $a Source: Dissertation Abstracts International, Volume: 66-06, Section: B, page: 3072.
500 $a Supervisor: Mien-Chie Hung.
502 $a Thesis (Ph.D.)--The University of Texas Graduate School of Biomedical Sciences at Houston, 2005.
520 $a To ensure the success of systemic gene therapy, it is critical to enhance the tumor specificity and activity of the promoter. In the current study, we identified the breast cancer-specific activity of the topoisomerase IIalpha promoter. We further showed that cdk2 and cyclin A activate topoisomerase IIalpha promoter in a breast cancer-specific manner. An element containing an inverted CCAAT box (ICB) was shown to respond this signaling. When the ICB-harboring topoisomerase IIalpha minimal promoter was linked with an enhancer sequence from the cytomegalovirus immediate early gene promoter (CMV promoter), this composite promoter, CT90, exhibited activity comparable to or higher than the CMV promoter in breast cancer cells in vitro and in vivo, yet expresses much lower activity in normal cell lines and normal organs than the CMV promoter. A CT90-driven construct expressing BikDD, a potent pro-apoptotic gene, was shown to selectively kill breast cancer cells in vitro and to suppress mammary tumor development in an animal model of intravenously administrated, liposome-delivered gene therapy. Expression of BikDD was readily detectable in the tumors but not in the normal organs of CT90-BikDD-treated animals. Finally, we demonstrated that CT90-BikDD treatment potentially enhanced the sensitivity of breast cancer cells to chemotherapeutic agents, especially doxorubicin and taxol. The results indicate that liposomal CT90-BikDD is a novel and effective systemic breast cancer-targeting gene therapy, and its combination with chemotherapy may further improve the current adjuvant therapy for breast cancer.
590 $a School code: 2034.
650 4 $a Biology, Genetics. $3 1017730
650 4 $a Health Sciences, Oncology. $3 1018566
690 $a 0369
690 $a 0992
710 2 0 $a The University of Texas Graduate School of Biomedical Sciences at Houston. $3 1019338
773 0 $t Dissertation Abstracts International $g 66-06B.
790 $a 2034
790 1 0 $a Hung, Mien-Chie, $e advisor
791 $a Ph.D.
792 $a 2005
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3180668